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In the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool for 
vaccination. In the following decades, an improved understanding of the mRNA pharmacology, 
together with novel insights in immunology have positioned mRNA-based technologies as 
next-generation vaccines. This review outlines the history and current state-of-the-art in mRNA 
vaccination, while presenting an immunological view on mRNA vaccine development. As such, 
we highlight the challenges in vaccine design, testing and administration, key considerations 
in the design of mRNA-based vaccines and new opportunities that arise when packaging 
mRNA in nanoparticulate vaccines. Finally, we discuss the mRNA self-adjuvant effect as a 
critical, but dichotomous parameter that determines the safety, efficacy and strength of the 
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Highlights 
 mRNA represents an attractive source of antigen in vaccination approaches 
 Both unformulated and nanoparticulate mRNA are used for direct in vivo vaccination 
 Nanoformulation widens the administration and delivery options for mRNA vaccines 
 The self-adjuvant effect of mRNA is a double-edged sword for vaccine efficacy 
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1. Introduction: the first steps in mRNA vaccine development 
The concept of exploiting mRNA as a novel therapeutic drug class has taken off in 1989, when 
a start-up biotech company in San Diego, called Vical Incorporated, published their first 
successes. They demonstrated that mRNA packaged within a liposomal nanoparticle could 
successfully transfect mRNA into a variety of eukaryotic cells [1]. A few months later, Wolff et 
al. reported on their experiments where ‘naked’, unprotected mRNA was directly administrated 
in the muscle of mice. Although this actually served as a control for their liposome-mediated 
delivery, i.m. injection of unformulated mRNA resulted in expression of the encoded protein 
during a couple of days [2]. These preliminary data provided the first evidence that in vitro 
transcribed (IVT) mRNA could deliver the genetic information to produce proteins within living 
tissue. Importantly, this could be achieved without the need of a virus or non-viral vector, which 
countered the existing scepticism about the stability of mRNA in vivo. This encouraged the 
idea that mRNA might offer a valuable and safe alternative to plasmid DNA. Indeed, as the 
mRNA molecules only have to reach the cytosol in order to be translated at the ribosomes, 
they avert the risk of being integrated into the host genome.  
Besides the therapeutic usage of mRNA to transiently replace faulty or missing proteins, it was 
suggested in the early 1990s that mRNA might be useful for the delivery of antigenic 
information to antigen-presenting cells (APCs) [3, 4]. As pioneers, Martinon et al. showed that 
liposomes containing mRNA encoding the influenza virus nucleoprotein elicited virus-specific 
cytotoxic T lymphocytes (CTLs) [3]. In addition to this cellular immunity, Conry et al. 
demonstrated the activation of humoral immune responses, as they confirmed that a 
prophylactic vaccine consisting of mRNA encoding a carcinoembryonic antigen resulted in the 
induction of anti-tumoral antibody responses [4]. After three decades of research, mRNA 
vaccines have reached a new momentum, with many promising candidates entering the 
clinical trial stage. In this review, we will outline the most important fundamental insights that 
have led to our current understanding on how mRNA vaccines should be formulated and 
delivered. We will discuss on how the immunological outcome might vary from one mRNA 
vaccine platform to another, and where there might be room for further improvement to induce 





Figure 1. Pioneering steps and milestones in the development of mRNA-based (cancer) 
vaccines. APC, antigen-presenting cell; PD-1, programmed cell death-1; TLR, Toll like 
receptor, RIG-I, retinoic acid -inducible gene I; IFN, interferon; NSCLC, non small cell lung 
carcinoma; LNP, lipid nanoparticle, IVT, in vitro transcribed; DC, dendritic cell; i.v., intravenous. 
*A few dozen phase I/II trials with mRNA vaccines are ongoing or recruiting patients, 
sponsored by leading biotech companies in the field. 
2. An immunological view on mRNA vaccines 
Shortly after the discovery of the dendritic cell (DC) in 1973 by Ralph Steinman and Zanvil 
Cohn, this cell type was identified as the accessory cell that is required to initiate T cell 
responses [5-7]. DCs are specialized in the uptake, processing and presentation of protein 
antigens to lymphocytes, which links innate and adaptive immune responses. Antigen 
signalling by DCs can either originate from the cytoplasm, which involves the presentation of 
antigenic peptides in major histocompatibility complex (MHC) class I molecules, or alternatively 
from the lysosomes that harbour fragments of endo- or phagocytized antigens which are 
loaded into MHC class II. These MHC complexes, thus loaded either with intracellular antigens 
in MHC-I or extracellular antigens in MHC-II, can then be recognized by the T cell receptor of 
CD8+ T cells or CD4+ T cells, respectively [8]. In addition to this antigen signalling, DCs fulfil 
their essential role in immunity by providing the necessary co-stimulation to trigger the 
activation of antigen-specific T cells. As a result, activated CD8+ CTLs can selectively eliminate 
cells that express this “foreign” antigen, such as infected host cells taken over by viruses, and 
tumor cells expressing “abnormal” proteins. CD4+ T helper cells, for their part, can provide the 
cognate help to further promote and support CTL activity. To achieve humoral immunity, B 
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cells require the recognition of extracellular antigens by the B cell receptor, as well as the 
interaction with activated T helper cells via the MHC class II pathway to enable the production 
of multifunctional, high-affinity antibodies. This knowledge on how DCs steer immune 
responses by specifically engaging different effector cells depending on the source and 
intracellular location of the antigen, has instigated the exploration of (cancer) vaccines, using 
different types of antigens.  
2.1. mRNA as an attractive source of antigen  
One of the key advantages of using antigen-encoding mRNA, is that it provides an easy way 
to evoke MHC-I presentation and elicit CTL responses. In similarity to viral infections, (IVT) 
mRNA allows the transient expression and accumulation of the selected antigens in the 
cytoplasm, which can then efficiently be processed into peptides and loaded in the MHC class 
I pathway, as illustrated in Figure 2. As such, the cytosolic presence of a few mRNA molecules 
can ensure extensive antigen presentation to CTLs, while proteins have to rely on less efficient 
cross-presentation pathways. Interestingly, also the MHC class II pathway can be targeted 
using mRNA as a source of antigen: this either after the secretion and recycling of the mRNA 
expressed proteins, or via direct shuttling of antigens from the cytosol to the lysosomes, e.g., 
promoted by the incorporation of a lysosomal targeting sequence in the mRNA construct [9, 
10]. By comparison with protein-based vaccines, it was recently found that the extended 
antigen availability that can be obtained via mRNA had a profound effect on the magnitude 
and the affinity maturation of antibody responses, resulting in a more durable protection [11-
13].  
Furthermore, mRNA has the advantage of offering a high degree of versatility in the type and 
number of antigenic determinants it encodes. For one, mRNA can code full-length proteins, 
thus avoiding restrictions concerning a patient’s MHC haplotype. Alternatively, tandem 
constructs can be engineered which connect multiple antigenic epitopes within a single mRNA 
strand. Using this strategy, the company BioNTech AG has developed personalized mRNA-
based cancer vaccines by identifying individual and immunogenic tumor mutations and 
producing on-demand mRNA vaccines encoding these neo-epitopes [14]. A first-in-human trial 
demonstrated the clinical feasibility and safety of this approach for advanced melanoma 
cancers: all vaccinated patients developed CD4+ and CD8+ T cell responses against the 
selected antigens, with some patients showing objective antitumor responses [15]. 
The fact that preparing a new mRNA construct tailored to a specific disease can be done in a 
straightforward and fast way, makes mRNA also an ideal candidate to trigger immunity against 
infectious diseases. These tend to rapidly mutate and therefore require a flexible and rapid 
production of appropriate vaccines that match the circulating viral strains. In this context, 
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prophylactic mRNA vaccines were already considered safe and effective in phase I clinical 
trials for infectious diseases, such as influenza and rabies [16-18]. In small and large animal 
models, mRNA vaccines were able to elicit immunity against emerging infections such as zika, 
ebola and HIV [19-23]. Moreover, by the “in situ” expression of proteins within the cell, mRNA 
can achieve the production of properly folded and glycosylated antigens, offering solutions to 
the challenging production and limited stability of protein antigens. Moderna Therapeutics 
generated an mRNA vaccine encoding the five different subunits of the pentameric complex 
of the cytomegalovirus (CMV). Together with an mRNA sequence against the CMV 
glycoprotein gB, this multiple-antigenic mRNA vaccine induced potent and durable neutralizing 
antibody titers in immunized mice and non-human primates [24].  
2.2. mRNA as danger signal 
Since the dawn of mRNA in vaccinology, the original model of immune recognition stating that 
T cells and B cells mount reactions against “non-self” proteins, while inducing tolerance against 
“self” proteins”, which was based on a clonal selection theory, was found to be inadequate. In 
1989, Charles Janeway proposed that antigen-presenting cells (APCs) should provide, in 
addition to a suitable antigenic determinant, a second co-stimulatory signal to activate 
lymphocytes. He stated that invading microbes are discriminated as non-self, not by the 
presence of foreign antigens, but through the existence of germline-encoded pattern 
recognition receptors (PRRs) that recognize infectious or microbial components, termed 
pathogen-associated molecular patterns (PAMPs) [25]. A few years later, Polly Matzinger 
elaborated on this concept and stated that APCs do not only respond to exogenous microbial 
signals, but are also activated by danger or alarm signals derived from damaged cells, such 
as heat shock proteins and extracellular nucleic acids [26]. The first real evidence to support 
this infectious non-self model and danger theory emerged in 1996, when Jules Hoffmann 
showed the involvement of Toll-like receptors (TLR) in how Drosophila reacts to pathogenic 
microorganisms. Interestingly, these TLRs had remarkable evolutionary conserved structural 
and functional similarities in mammals [27]. Two years later, the identification of TLR4 as the 
PRR that recognizes bacterial lipopolysaccharide (LPS) in mice by the group of Beutler, truly 
added flesh to the bones of this concept [28].Together with the pioneering work of Ralph 
Steinman in DC biology, these discoveries revolutionized our understanding of how immune 
responses are initiated and regulated.  
While it has long been known that (‘foreign’) mRNA induces the production of type I interferon 
(IFN), in particular IFN-α and IFN-β, the exact mechanisms of mRNA’s intrinsic immunogenicity 
remained unclear [29]. In the early 2000s, mRNA delivery was shown to trigger an antiviral 
activation state in DCs, which involves the recognition of single-stranded RNA through TLR7 
and TLR8 located in the endosomes [30, 31]. By the formation of secondary RNA structures 
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or through the introduction of contaminants of double-stranded (ds) RNA fragments during the 
IVT mRNA production process, immune activation can be triggered via the endosomal TLR3 
pathway. In addition to these TLRs, dsRNA was shown to activate the cytosolic RNA sensors 
retinoic acid inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 
(MDA5) [32-34].  
The binding of mRNA molecules to these danger sensors leads to downstream signalling via 
specific adaptor molecules (i.e. MyD88 for TLR7/8 and TRIF for TLR3), eventually resulting in 
the production of type I IFN and other pro-inflammatory cytokines (e.g., IL-6 and TNF-α). In 
turn, type I IFNs bind autocrine or paracrine receptors, activating the Janus kinase-signal 
transducer activator of transcription (JAK-STAT) pathway, which regulates the gene 
expression of hundreds of proteins involved in antiviral immunity [35, 36]. Hence, these 
signalling pathways coordinate the activation and promotion of distinct innate and adaptive 
immune responses, referred to as the “self-adjuvant effect” of mRNA.  
 
 
Figure 2. Mode of action of mRNA to induce adaptive immune responses. 1. Delivery: 
antigen-encoding mRNA should resist degradation by RNases and preferably reach APCs 
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(DCs). mRNA molecules are taken up by receptor-mediated endocytosis and routed through 
the endo-lysosomal compartment. Only a fraction of mRNA escapes the endosomes, 
associates to eIF4E proteins, and binds to the ribosomes, while the largest amount of mRNA 
molecules is degraded. 2. Adjuvant: mRNA is recognized by several PRRs, including 
endosomal TLRs and cytosolic RNA sensors, inducing signalling pathways that regulates the 
production of type I IFNs and other pro-inflammatory cytokines. Type I IFNs act as a double-
edged sword: it initiates the transcription of hundreds of interferon-stimulated genes (ISGs) 
involved in the DC maturation process and directly acts as a third cytokine signal for T cell 
activation, but also promotes antiviral enzymes that enhances mRNA degradation and inhibits 
the mRNA translation process. 3. Antigen presentation: the expression of antigenic proteins 
by the host translation machinery allows the antigen processing and presentation of antigenic 
peptides via the intracellular MHC-I pathway to CTLs, or allows the “in situ” production of 
secreted-antigen proteins that can be presented through the MHC-II pathway to helper T cells 
and B cells. 
2.3. The paradigm for mRNA vaccine development 
A number of mRNA vaccine platforms have emerged over the years. The basic structure of 
IVT mRNA closely resembles “mature” eukaryotic mRNA, and consists of (i) a protein-
encoding open reading frame (ORF), flanked by (ii) 5′ and 3′ untranslated regions (UTRs), and 
at the end sides (iii) a 7-methyl guanosine 5′ cap structure and (iv) a 3′ poly(A) tail (see Figure 
3). The non-coding structural features play essential roles in the pharmacology of mRNA and 
can be individually optimized to modulate the mRNA stability, translation efficiency, and 
immunogenicity [35, 37, 38].  
In 2004, Karikó and colleagues observed, while exposing ex vivo human DCs to mRNA from 
different sources, that these cells tolerated mammalian mRNA, while strong inflammatory 
cytokine responses were detected upon the delivery of mRNA derived from bacteria, necrotic 
mammalian cells and IVT mRNA [39, 40]. Interestingly, they found that the strongly reduced 
immune-modulatory capacity of endogenous mRNA could be attributed to the presence of 
modified nucleotides in the mRNA construct, such as methylated nucleosides or 
pseudouridine. As such, it was established that naturally occurring post-translational 
modifications to the mRNA nucleotides prevent the immune detection of endogenous mRNA, 
which allows the cells to discriminate it from pathological or invading mRNA. This presented 
new opportunities for mRNA development: by incorporating modified nucleosides, mRNA 
transcripts referred to as “nucleoside-modified mRNA” could now be produced with reduced 
immunostimulatory activitiy, and therefore an improved safety profile. In addition, modified 
nucleosides allowed the design of mRNA vaccines with strongly enhanced stability and 
translation capacity, as they could avoid the direct antiviral pathways that are induced by type 
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IFNs and are programmed to degrade and inhibit invading mRNA [41-45]. For instance, the 
replacement of uridine with pseudouridine in IVT mRNA was found to reduce the activity of 2'-
5'-oligoadenylate synthetase, which regulates the mRNA cleavage by RNase L. In addition, 
lower activities were measured for protein kinase R, an enzyme that is associated with the 
inhibition of the mRNA translation process. In a therapeutic setting, Kormann et al., 
demonstrated that nucleoside-modified mRNA encoding erythropoietin (Epo), in which 25% 
thio-uridine and 25% 5-methylcytidine was incorporated, resulted in five times higher Epo 
levels compared to untreated mice, two weeks after i.m. administration. In contrast, no 
significant changes were detected with unmodified mRNA, which only evoked a substantial 
immune activation [44]. 
Besides the incorporation of modified nucleotides, other approaches have been validated to 
increase the translation capacity and stability of mRNA. One example is the development of 
“sequence-engineered mRNA”. Here, mRNA expression can be strongly increased by 
sequence optimizations in the ORF and UTRs of mRNA, for instance by enriching the GC 
content, or by selecting the UTRs of natural long-lived mRNA molecules [46-50]. Another 
approach is the design of “self-amplifying mRNA” constructs [51, 52]. These are mostly 
derived from alphaviruses, and contain an ORF that is replaced by the antigen of interest 
together with an additional ORF encoding viral replicase. The latter drives the intracellular 
amplification of mRNA, and can therefore significantly increase the antigen expression 
capacity [53]. Already in 1995, Johanning et al. found that the i.m. injection of self-amplifying 
mRNA derived from the Sindbis virus, resulted in a ten-fold increase in protein expression 
levels, which could be maintained much longer (from 2 days up to 10 days) compared to 
nonamplifying mRNA [51]. 
Also, several modifications have been implemented at the end structures of mRNA. Anti-
reverse cap (ARCA) modifications can ensure the correct cap orientation at the 5' end, which 
yields almost complete fractions of mRNA that can efficiently bind the ribosomes [54]. Other 
cap modifications, such as phosphorothioate cap analogs, can further improve the affinity 
towards the eukaryotic translation initiation factor 4E (eIF4E), and increase the resistance 
against the RNA decapping complex [55, 56]. Correlations were found between the elongation 
of the poly(A) tail of mRNA and the duration of expression, and specific modifications at the 3’ 
UTR were reported that can slow-down the decay of the poly(A) tail by deadenylation [57, 58]. 
Also, more exotic approaches have been suggested, such as the generation of circular-
engineered RNAs that render resistance towards exonuclease-mediated degradation [59, 60]. 
Recently, it was demonstrated that the delivery of synthetic polyamine complexes pre-
assembled with mRNA and eIF4E proteins resulted in significantly higher expression 
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efficiencies compared to mRNA alone, which could be attributed to a higher stability and 
recruitment of these complexes to the ribosomes [61]. 
Conversely, by modifying its structure, the potency of mRNA to trigger innate immune 
responses can be further improved, but to the detriment of translation capacity. The company 
CureVac AG found that by stabilizing the mRNA with either a phosphorothioate backbone, or 
by its precipitation with the cationic protein protamine, antigen expression was diminished, but 
stronger immune-stimulating capacities could be obtained [62, 63]. This instigated the 
development of protamine-complexed mRNA molecules to function either solely as an immune 
adjuvant for peptide and protein-based vaccines (i.e. RNAdjuvant®), or in a two-component 
mRNA platform consisting of antigen-encoding mRNA combined with protamine-mRNA 
complexed molecules in order to increase the vaccine’s immunogenicity (i.e. RNAactive®) [64, 
65]. 
Taken together, these findings resulted in a paradigm of the design of mRNA formulations for 
vaccination. One strategy is to use mRNA which is fully optimized to obtain a strong adjuvant 
effect, another is to work with ‘modified’ mRNA with high translation capacity, and thus 
improved antigen bio-availability [43, 62]. With respect to vaccination purposes, one should 
consider that the modifications that favour the mRNA’s translation capacity involve a partial or 
complete reduction of the interaction between mRNA molecules and one or multiple virus-
specific PRRs [66]. As such, this might come at the cost of the adjuvant effect of the mRNA 
vaccine. After all, both outcomes are oppositely regulated by type I IFN-induced genes. The 
priority is often given to the translation capacity of mRNA with the idea to improve the antigen 
availability. Yet, from an immunological point-of-view, the innate immune sensing of mRNA, 
which evokes the phenotypic immune profiling and cytokine milieus, is at least equally 
important. Indeed, these innate immune signals will trigger and guide the choice of effector 
responses, which is of essential importance for the vaccine’s therapeutic value [67]. 
Notwithstanding, the potency of this self-adjuvant effect of mRNA must be weighed against the 
risk of any adverse reaction inherent to it, including inflammation reactions and auto-immune 
events [68]. This key challenge of finding an optimal balance between the translation capacity 
and adjuvanticity of mRNA vaccines, in order to obtain adequate, but safe immunogenicity, will 




Figure 3. Structural features of IVT mRNA. Figure shows the structural elements of IVT 
mRNA. Each of these elements can be optimized and modified in order to modulate the 
stability, translation capacity, and immune-stimulatory profile of mRNA. 
3. mRNA vaccine delivery 
3.1. The in vivo approach 
The first human trials evaluating mRNA delivery were focused on an ex vivo approach, where 
monocyte-derived DCs were transfected with antigen-encoding mRNA and re-infused into the 
patients as a cellular vaccine [69]. Excellent reviews on such mRNA-based DC vaccines can 
be found elsewhere [70, 71]. Over the years, the focus has started to shift towards the direct 
administration of mRNA. In general, the alternative of in vivo approaches that directly target 
mRNA to APCs, holds a number of key benefits to ex vivo generated DC vaccines. First of all, 
the costly and laborious ex vivo steps associated with the isolation and culturing of patient-
specific DCs are avoided. Secondly, the in vivo delivery of mRNA more closely mimics a 
natural (viral) infection, which may benefit the vaccine’s efficacy; multiple immune cells and 
non-immune cells can be directly transfected in their natural habitat, which allows the 
immediate innate immune activation and coordinated signalling to adaptive immune cells. 
Moreover, crucial immune events, such as the release of inflammatory cytokines and 
chemokines, that peak within a couple of hours after transfection, can be lost in time and place 
when preparing ex vivo DC vaccines [72, 73]. 
Despite the numerous advantages of mRNA vaccines to target APCs in situ, there are also a 
number of challenging technical hurdles that need to be overcome for mRNA to be successfully 
delivered to their target cells. Independent of the administration route, several evolutionary 
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barriers are designed to prevent any intrusion of foreign nucleic acids and thus limit the delivery 
of exogenous mRNA [74]. In the early events after administration, mRNA should resist the 
degradation by RNAses present in the tissues and bloodstream. Since mRNAs are large and 
polyanionic molecules, they cannot passively diffuse across the cell membrane. Therefore, 
mRNA molecules rely on active transportation via endocytic uptake mechanisms. This implies 
that even when intact mRNA is taken up by APCs, almost all mRNA molecules will eventually 
be entrapped and degraded in the endo-lysosomal compartment. Moreover, anti-viral host 
defence mechanisms are induced by the mRNA immune recognition increasing enzymatic 
activities that destroy mRNA and inhibit its further cellular translation (see section 2.2) [45].  
3.2. Naked, or unprotected mRNA vaccines for local delivery 
Despite these well-documented delivery hurdles, ‘naked’, unprotected mRNA has been 
evaluated to trigger protein expression after injection via different administration routes. The 
earliest studies have explored the i.m., subcutaneous (s.c.), and intradermal (i.d.) routes, 
showing detectable protein expression levels at the injection site, which also resulted in 
adaptive immune responses [4, 51, 75]. Little by little, more came to be known on the mode of 
action of these ‘naked’ mRNA vaccines, and the cell subsets involved in the response. In 2007, 
Probst et al. proved that somatic cells of the dermis, such as muscle cells, fibroblasts or 
keratinocytes, are capable of taking up β-galactosidase-coding mRNA in a saturable and ion-
dependent manner [76]. More details on mRNA uptake were uncovered by Lorenz et al., who 
used a fibroblast cell line to demonstrate that mRNA molecules are initially recognized by 
scavenger receptors prior to their internalization by caveolae and lipid raft-dependent uptake 
mechanisms [77]. With respect to their intracellular fate, they showed that mRNA molecules 
are routed through the endocytic pathways, with the largest fraction ending up in the 
lysosomes, while only a limited fraction of mRNA molecules is being released to the cytosol. 
Only years later, the involvement of immune cells in the uptake of unformulated mRNA was 
identified: skin-resident DCs were capable of engulfing naked mRNA via macropinocytosis and 
could trigger T cell immunity in mice [78]. The involvement of different cell types in the uptake 
of mRNA vaccines was confirmed for the RNActive® vaccine technology. Upon i.d. application, 
both vaccine components, sequence-engineered mRNA and protamine-complexed mRNA, 
were taken up by both immune cells and non-immune cells, with the highest frequencies 
detected within macrophages, DCs and neutrophils [79]. This coincided with an increased 
expression of activation markers by resident APCs, as well as a transient production of distinct 
cytokines and chemokines, demonstrating the self-adjuvanticity of this formulation. In addition 
to these rather locally induced effects, two independent studies respectively testing RNActive® 
or a formulation of sequence-engineered mRNA alone, suggested the migration of activated 
15 
 
immune cells toward the lymph nodes (LNs), as they could also detect innate immune signals 
and mRNA-encoded antigens in the draining LNs [79, 80] 
Over the years, it became clear that the chosen injection route plays a major role regarding 
the cell types that come in contact with the mRNA and the potency of the evoked immune 
response. As such, direct delivery of the mRNA into the LNs (i.n. injections) rapidly became a 
favourable delivery route to ensure delivery to APCs. This was underscored by Kreiter and 
colleagues, who reported that the potency of an unmodified, naked mRNA vaccine to induce 
T cell immunity could be drastically increased by injecting it i.n. compared to injections in the 
skin [81]. They demonstrated that within the LNs, naked mRNA was predominantly taken up 
by resident DCs (and macrophages) via macropinocytosis [82]. Furthermore, the increasing 
knowledge on the extensive infiltration of immune cells into various tumor types, also prompted 
the investigation of intratumoral (i.t.) application of naked mRNA. Indeed, tumor-infiltrating 
CD8a+ cross-presenting DCs were mainly responsible for mRNA uptake after injection in 
different subcutaneous murine tumor models, resulting in mRNA expression for >5 days [83, 
84].  
Of note: this story may drastically change when evaluating self-amplifying mRNA. First of all, 
it was found that APCs could not be directly transfected with self-amplifying mRNA, which is 
significantly longer in length (10kb versus 2-3 kb for nonamplifying mRNA). Nevertheless, this 
inability to directly transfect APCs, did not abrogate the priming of CTLs following the i.m. 
delivery of a self-amplifying mRNA vaccine [85]. To elucidate the underlying mechanisms, 
Lazzaro et al. investigated the respective contribution of (transfected) muscle cells and (non-
transfected) professional APCs to the CTL priming. They concluded that APCs could take up 
antigens that were produced by the transfected muscle cells, and that cross-presentation of 
the myocyte-expressed antigens was the mechanism leading to the induction of CTL 
responses [85]. As such, the transfection of somatic cells, such as myocytes, may contribute 
to the magnitude and duration of antigen availability, while the activation of TLR and cytosolic 
RNA sensors in these cells can lead to local inflammation and infiltration of cross-presenting 
DCs.  
In attempts to further promote innate immune activation, combinations of antigen-encoding 
(unmodified) mRNA and immune-attractants or immunostimulants were tested, which were 
implemented in the vaccine as protein or as mRNA transcripts. Intradermal injections of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) contributed to the infiltration of 
monocytes, and to the migration of mRNA-transfected, matured DCs to the LNs [86, 87]. The 
co-delivery of immune adjuvants, such as polyinosinic:polycytidylic acid (Poly(I:C)) and 
lipopolysaccharide (LPS), was found to rapidly mature the APCs, which abrogated the cellular 
uptake of mRNA molecules [82]. As such, these adjuvants caused a detrimental reduction of 
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the mRNA transfection capacity, thus antigen bio-availability for T cell priming. Alternatively, 
Van Lint et al. showed increased T cell stimulatory effects by the administration of a mixture of 
four naked mRNAs encoding an antigen and three additional immunomodulatory molecules; 
CD40 ligand, constitutive active TLR 4 and CD70, patented as the TriMix mRNA technology 
by the ‘Vrije Universiteit Brussel’ (VUB), and licensed to eTheRNA immunotherapies [88]. The 
TriMix technology is currently under clinical investigation as an mRNA immunotherapeutic for 
melanoma and breast cancer, where the mixture of naked, unmodified mRNA sequences is 
respectively delivered i.n. or directly into accessible tumor lesions. Recently, an i.n. 
administered TriMix mRNA vaccine was shown to be safe and well tolerated in a dose-
escalation clinical study against HIV-1 infection, while obtaining moderate HIV-specific T cell 
responses at high doses (total mRNA dose of 1.2 mg) [89]. 
3.3. Advanced delivery systems for mRNA 
3.3.1. Nanoparticles: opening new avenues 
Despite the successes obtained with naked mRNA, research towards nanoparticle carriers for 
the delivery of mRNA vaccines was initiated. The rationale behind this, was that mRNA 
nanomedicines could act as multi-functional agents that widen the options with respect to 
vaccine delivery. For one, as mRNA within nanoparticles is much better protected against 
enzymatic degradation conditions, new delivery avenues such as i.v. administration become 
possible. Furthermore, by formulating mRNA as a nanoparticle, it allows to alter its 
biodistribution, cellular targeting and cellular uptake mechanism, in such a way that it can 
contribute to the delivery of mRNA and vaccine’s outcome. 
Although it is clear that the choice and optimisation of a nanoparticle is essential to achieve 
successful mRNA transfection, it is important to realize that many studies suggest that the 
transfection experiments in cultured cells may not reliably predict the in vivo behaviour of 
mRNA formulations. This glaring discrepancy between the in vitro and in vivo delivery of mRNA 
was further demonstrated by Bhosle et al., who observed that completely different cellular 
uptake pathways were involved in vitro and in vivo, and this for both naked mRNA as well as 
a lipid-based nanoparticle (LNP) containing mRNA [90]. Moreover, using a high throughput 
system, Paunovska et al. were able to test hundreds of LNPs for the nucleic acid delivery to 
macrophages or endothelial cells after i.v. delivery, but found almost no in vitro-in vivo 
correlations [91]. These studies raise the question whether it is entirely Utopian to believe that 
nanoparticle-based strategies can be rationally designed to fulfil their multi-functional role as 
mRNA vaccine-enhancing moieties. In the following sections, we will discuss some of the key 
considerations when designing nanoparticles for mRNA vaccination, with a particular focus on 
mRNA LNPs, as these have already made it to the (early) stages of clinical testing [16, 92]. 
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For the reader’s interest, extensive summaries of the chemically distinct nanoparticle 
compositions for mRNA delivery including, but not limited to, protamine, lipids or polymers, as 
well as hybrid formulations can be found elsewhere [38, 93]. 
3.3.2. Designing and preparing lipid nanoparticles for mRNA delivery 
The lipid formulations that have been tested for the delivery of mRNA are typically composed 
of a cationic/ionizable lipid and other “helper” lipids, such as a phospholipid, cholesterol and/or 
a poly(ethylene glycol) (PEG) lipid (see Figure 4). The cationic lipids are generally included to 
allow electrostatic complexation of the negatively charged mRNA molecules, and can roughly 
be subdivided according to the pKa of the amino group into (i) “permanently-charged lipids”, 
such as DOTMA, DOTAP and DC-cholesterol [1, 94, 95], or (ii) “pH-dependent ionizable 
lipids”, such as D-Lin-MC3-DMA and the lipid-like molecule C12-200 [96-99]. These ionizable 
lipids (pKa < 7), originally optimized for siRNA delivery, have a neutral to mildly cationic charge 
under physiological pH conditions. This offers certain benefits over the permanently-charged 
lipids, the foremost of which is that ionizable lipids have been associated with a reduced toxicity 
and a prolonged blood circulation lifetime [100, 101]. The other lipid components are 
considered “helper lipids”, owing to their distinct functional properties which may affect the 
structural arrangement of the complexed mRNA LNPs to improve their stability or promote the 
intracellular uptake and cytosolic entry of mRNA (LNPs) [102]. 
 
Figure 4. Schematic representation of mRNA lipid nanoparticles. The choice of the 
amino lipids (cationic or ionizable lipids) and helper lipids will have an impact on the 
structural arrangement and functional properties of the formulated mRNA LNPs. A proper 
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balance needs to be find in order to obtain enough particle stability in a biological context, 
while inside the target cells the mRNA cargo should be dissociated and the LNPs should 
promote the endosomal release of mRNA. 
One of the key barriers that affects the overall transfection efficiency, is endosomal degradation 
of the engulfed mRNA LNPs. As a result, a lot of effort is made to modify and optimize 
candidate mRNA LNPs to facilitate the endosome-to-cytosol transition of the mRNA cargo. 
The mechanism behind the endosomal release of mRNA was suggested to depend on a lipid-
mixing step of the LNPs’ protonated (“ionized”) lipids and anionic phospholipids of the 
endosomal membrane [103-105]. The ion pair formation between these lipids would trigger a 
membrane fusion and membrane destabilization, which in turn enhances the escape of mRNA 
molecules from the endosomes. Additionally, this lipid exchange was suggested to induce a 
non-bilayer structure conversion (i.e. lamellar-to-inverted hexagonal phase), which would 
dissociate LNPs and support the destabilization of the endosomal membrane [106]. Studies 
have linked the structural organization of the mRNA and lipid components to the eventual 
transfection efficiency that can be achieved. Note that the physicochemical and structural 
characteristics of mRNA LNPs will depend on the lipid composition, the ratio of mRNA to the 
total amount of (cationic) lipids, and the LNP synthesis (for a detailed review on these 
parameters also see [107]). 
When mRNA LNPs are prepared by admixing mRNA with pre-formed (monolamellar) 
liposomes containing a permanently-charged lipid, it is assumed that the liposomes re-
organize to form a multi-lamellar structure in which mRNA molecules are “sandwiched” in 
between concentric lipid bilayers [108]. The addition of saturated phospholipids, such as DPPC 
and DSPC, increases the phase transition temperature of the cationic liposomes and supports 
the formation of such a lamellar lipid bilayer structure [102]. By contrast, the unsaturated 
phospholipid DOPE facilitates the formation of a non-lamellar lipid phase (i.e. inverted 
hexagonal phase), which was found to contribute to the endosomal escape [109]. However, 
the latter may hold true only in in vitro conditions. In preclinical testing, the incorporation of 
DOPE was linked to an increased serum-induced disintegration of cationic (DNA) LNPs and 
thus poor in vivo transfection efficiency [110].  
Another mRNA LNP production strategy is ethanol dilution, which is a suitable method for 
preparing the more technically advanced LNP systems containing ionizable lipids. Here, the 
individual lipids are dissolved in ethanol, which is then rapidly mixed with mRNA in an acidic 
aqueous buffer. By diluting the ethanol phase, the lipids undergo a condensation process and 
form LNPs while efficiently entrapping the mRNA. This is then followed by a dialysis step into 
neutralizing buffer to remove ethanol and neutralize the pH. The mechanism of the formation 
of these ionizable LNP systems (with different nucleic acid payloads) has recently been 
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elucidated by Kulkarni and colleagues [111, 112]. They proposed that in the rapid-mixing step 
at acidic pH, (“empty”) small liposomal structures and (“loaded”) larger electron-dense particles 
are formed. Next, during the dialysis step these particles undergo fusion as the pH is 
neutralized, which generates the final LNP system. Furthermore, they demonstrated that the 
PEG-lipid content dictates the eventual LNP size by exerting repulsive forces at the particle 
surface that limits further fusion. In another study, Yanez Arteta et al. indicated that the 
structural arrangement of mRNA LNPs based on D-Lin-MC3-DMA, DSPC, cholesterol and a 
PEG-lipid exhibited a disordered inverse hexagonal phase containing D-Lin-MC3-DMA, 
cholesterol, water and mRNA. This core was surrounded by a lipid monolayer containing 
mainly the DSPC and DMPE-PEG2000 content, as well as a fraction of D-Lin-MC3-DMA and 
cholesterol [113]. Interestingly, by adjusting the molar ratios of the different lipids, the authors 
could produce mRNA LNPs with varying surface characteristics. They found that LNP 
compositions that favour a partial segregation of D-Lin-MC3-DMA lipids from the internal core 
to the outer surface, correlated with an increased transfection efficiency. By contrast, mRNA 
LNPs with an enriched DSPC content at the surface (approaching an almost pure monolayer 
of DSPC) exhibited a weak transfection capacity. In addition, the authors suggested that an 
enrichment of cholesterol might result in the formation of nanocrystals at the LNP surface. 
Although this was not further investigated in this study, prior reports have linked the occurrence 
of cholesterol nanocrystals to an improved transfection efficiency [114, 115].  
Notably, bench-top microfluidic mixing devices are available for the production of unloaded 
liposomes or mRNA LNPs via this ethanol-dilution principle, with the potential to be scaled up 
for clinical or industrial purposes [116]. These microfluidic devices producing LNPs in a well-
controlled and high-throughput manner have certainly advanced the clinical translation of novel 
LNPs for gene delivery. Besides facilitating the production process, the rapid screening of 
novel lipid libraries has helped to continually optimize lipid compositions. Furthermore, this has 
also supported the discovery of new lead ionizable lipids holding greatly improved potency and 
safety for mRNA transfection [117-119]. 
Besides progress in the LNP design and production, novel insights in the mode of action to 
transfect cells in vivo is crucial for further development. Although the theory of membrane 
fusion has been around for more than a decade, the mechanism of LNPs to promote the 
cytosolic delivery of mRNA cannot be reduced to merely this single aspect [120]. More recent 
studies describe that the endocytic trafficking of mRNA LNPs is a dynamic process, which 
involves recycling pathways and signalling pathways that affect the cytosolic entry and 
translation of mRNA. For instance, the transporter Niemann-Pick Type C-1, located on late 
endolysomes, was found to be responsible for the exocytosis of a large fraction of internalized 
(si)RNA LNPs, hence strongly reducing the cytosolic delivery [121]. By contrast, the 
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recruitment of the mechanistic target of rapamycin complex 1 to the lysosomal membrane was 
key to trigger the translation of delivered mRNA [122].  
Less investigated, but possibly equally important, is the relationship between the mechanism 
of cellular entry and the intracellular trafficking of mRNA. By targeting mRNA LNPs to selective 
surface receptors expressed by DCs, the particles may be routed into intracellular trafficking 
pathways that are less degradative for the mRNA cargo [123]. As such, (mRNA) nanovaccines 
have been targeted towards the C-type lectins DEC-205, CLEC9A and mannose receptor, 
which are also involved in pathways that favour the uptake, endocytic protection and cross-
presentation of dead cell antigens [124-126].  
3.3.3. The administration of mRNA LNPs 
Another key parameter that will determine the efficacy and safety of mRNA LNPs is the choice 
of administration route (see Figure 5). Importantly, depending on the administration route, 
specific extracellular barriers might be encountered which prompts specific particle 
optimizations. The skin represents a very convenient route, which can result in an immune 
response by two separate mechanisms: either mRNA LNPs locally transfect and activate APCs 
which consequently migrate to the lymphatics, or the mRNA LNPs are passively drained via 
the lymphatic system, thus delivering the mRNA payload directly in close proximity to LN-
resident APCs and T cells. 
In a detailed study in rhesus macaques, Liang et al. investigated the immune cell infiltration, 
vaccine uptake, immune activation and mRNA translation after either i.m. or i.d. injection of an 
ionizable LNP formulated with nucleoside-modified mRNA [127]. For both administration 
routes, they could show a rapid recruitment of neutrophils, monocytes and different DC subsets 
to the injection site (skin or muscle). Although all of these cell types were able to internalize 
mRNA LNPs, only monocytes and myeloid DCs showed high translation of the mRNA. In 
addition, they could detect mature, mRNA-transfected APCs in the draining LNs. With respect 
to the resulting immune response, they showed that i.d. delivery resulted in an earlier activation 
of skin DCs and a more efficient migration to draining LNs, as well as a prolonged antigen 
availability at the injection site. Together, this resulted in a superior immunogenicity compared 
to i.m. delivery, as i.d. injection resulted in the highest antibody titers and CD4+ T cell activation.  
Based on prior reports, particle size is a critical factor to obtain efficient lymphatic transport of 
nanoparticles. Reports suggest that nanoparticles up to 200 nm are able to enter the lymphatic 
vessels, whereas larger particles are withheld at the injection site [128-130]. PEGylation 
accelerates the drainage of (lipid) nanoparticles into the lymphatic system, while targeting 
ligands such as mannose and antibodies against selective DC receptors can increase the 
entrapment of liposomes inside draining LNs [131-133]. In addition, studies suggested that 
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PEGylation is required to prevent a complete immobilization of the particles in the extracellular 
matrix (ECM) of the skin, explained by the fact that ECM components, such as 
glycosaminoglycans can inhibit both the distribution and cellular uptake of non-PEGylated 
LNPs at the injection site [134]. To give an example of an optimized mRNA LNP for lymphatic 
transport, Wang et al. generated a nanoparticle system consisting of a pre-condensed core of 
mRNA and calcium phosphate, stabilized by DOPA and coated by a lipid shell of DOTAP and 
DSPE-PEG[135]. These mRNA nanoparticles had a relatively small particle size (<50 nm), and 
an uncharged, strongly PEGylated outer-surface. As such, this system was found to efficiently 
traffic into the lymphatics, with a detectable mRNA presence in the draining LN as early as 4 h 
after s.c. injection, enabling the direct delivery of (almost the complete dose of) mRNA to LN-
resident macrophages and DCs.  
In the specific case of cancer immunotherapy, it was proven essential to evoke a systemic 
immune response to obtain antitumor immunity, which makes i.v. delivery a highly appealing 
administration route for mRNA-based cancer vaccines [92, 136, 137]. It is beyond any doubt 
that particle features such as size, surface charge, and structural conformation might 
drastically change once the mRNA LNPs enter the bloodstream. Indeed, the interaction of 
(mRNA) nanoparticles with biological fluids, gives rise to the adsorption of endogenous 
proteins and other biomolecules to the particular surface, resulting in the formation of a 
biomolecular or protein corona [138]. This may reduce the colloidal stability of the mRNA LNPs, 
followed by the aggregation of the particles and a premature release of the mRNA cargo [139, 
140]. Therefore, it is good practice to determine the size, stability and mRNA encapsulation 
efficiency of LNPs in undiluted biological media, using advanced microscopy methods such as 
fluorescence single particle tracking (fSPT, for LNP size and aggregation) and fluorescence 
correlation spectroscopy (FCS, to determine the degree of mRNA complexation) [139-141]. It 
is also possible to tweak the serum stability of LNPs by modifying their helper lipid composition. 
For one, cholesterol is typically used to increase the rigidity of LNPs (i.e. reducing the 
permeability of the lipid membrane), and therefore contributes to improved LNP stability and 
integrity in the presence of serum [110, 142]. Alternatively, the incorporation of PEGylated 
lipids is widely used to provide a “stealth effect”. This reduces the overall protein adsorption, 
and improves the colloidal stability of LNPs, but also hampers the LNP cellular uptake and 
transfection capacity [143]. Here, PEG-lipids with shorter acyl chains can provide an efficient 
strategy to overcome this “PEG-dilemma”. These PEG-lipids can gradually diffuse out of the 
LNPs, and thus temporarily confer stealth properties to the LNP system, while achieving higher 
transfection efficiencies compared to the longer, persistent PEG-lipids [139, 144]. 
From another vantage point, the formation of such a biomolecular corona, provides the 
nanoparticle with new (surface) properties, which could potentially be exploited to target and/or 
22 
 
enhance delivery [138, 145]. Importantly, the amount and identity of the individual proteins 
present in this biomolecular corona will depend on both the (“original”) nanoparticle 
characteristics and its biological context [138]. In general, i.v. injected nanoparticles are known 
to react with opsonic blood proteins, such as complement fragments, immunoglobulins, and 
fibronectin, which facilitates uptake by phagocytic cells, hence nanoparticle clearance [146, 
147]. Recently, Vu et al. elucidated how nanoparticles mediate complement activation, and 
found this to be quite universal over a range of clinically approved liposomes [148]. The 
creation of a biomolecular corona causes the exposure of self-epitopes, to which naturally 
occurring antibodies can bind. Merely a few surface-bound immunoglobulin molecules are 
sufficient to trigger complement activation. Several studies suggested that natural opsonisation 
processes might be manipulated as a passive strategy of targeting APCs [149, 150], or that it 
is possible to use the complement cascade as a danger signal for vaccination purposes [151]. 
Others have linked extensive complement activation with idiosyncratic infusion reactions to 
nanomedicines, clinically manifested as cardiopulmonary distress. However, recent findings 
suggest that these nanoparticle-mediated infusion reactions are triggered by an acute 
intoxication of pulmonary intravascular macrophages [152-154].  
PEGylation strategies have been used to mitigate the nanoparticle recognition and rapid 
clearance by phagocytic cells. Schöttler et al. demonstrated that PEGylated nanoparticles 
evade the macrophage system, not only by lowering the deposition of complement fragments 
and immunoglobulins on the nanoparticle surface, but rather by a selective higher presence of 
clusterin that functions as a strong dysopsonin [143]. However, PEGylation also has its 
limitations: in patients with pre-existing anti-PEG antibodies, infusion of PEGylated LNPs is 
contra-indicated, as this could lead to an even stronger complement activation as well as an 
accelerated blood clearance of PEGylated nanoparticles. This warrants precautions for the 
sensitization to PEG and prompts the investigation of novel “stealth” strategies [143, 148, 155].  
It should be noted that detailed studies on the role of the biomolecular corona formation and 
its dynamics on LNPs are still very limited. However, further progress in this field might discover 
new insights in the variations that have been found in the biodistribution and cell-specific 
targeting after the systemic delivery of distinct (mRNA) LNP formulations. As example, Akinc 
et al. found that the selective adsorption of apolipoprotein E onto an ionizable (neutral) LNP 
was responsible for the specific and potent delivery of (si)RNA to hepatocytes through receptor 
mediated endocytosis [156]. In comparison, cationic mRNA LNPs composed of a cationic lipid 
and cholesterol, or DOPE were found to primarily target the lungs, where they transfect tissue-
resident DCs, macrophages and endothelial cells [142, 157, 158]. Interestingly, by lowering 
the lipid-to-mRNA ratio to a lower lipid content, Kranz et al. demonstrated that DOTMA-DOPE 
mRNA LNPs become negatively charged and specifically target DCs in the spleen [92, 158]. 
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This finding of specifically targeting anionic mRNA LNPs to the spleen could be confirmed in a 
patient participating in a phase I trial for melanoma [159]. While it is possible that the observed 
site-specific targeting could be attributed to the LNP surface charge, the involvement of a 
different biomolecular corona cannot be excluded. Therefore, a detailed comparison between 
the biomolecular corona of these differently charged mRNA LNPs could be useful to further 
elucidate the mechanism behind the observed variety in organ distribution and cell-targeting 
after i.v. administration. 
As mentioned previously, antibodies or other targeting moieties can be incorporated in the LNP 
system to support selective organ disposition of mRNA LNPs, or to promote receptor-mediated 
uptake by specific (immune) cell types. To give a few other examples, Parhiz et al. 
demonstrated that ionizable mRNA LNPs conjugated with antibodies against the vascular cell 
adhesion molecule, PECAM-1, promoted the mRNA transfection of endothelial cells in the 
lungs after systemic delivery [160]. Perche et al. prepared mannosylated nanoparticles loaded 
with mRNA, which could be used as an active targeting strategy to enhance the transfection 
of splenic DCs [126]. For a more elaborated summary on potential target receptors and 
technical details on ligand conjugation strategies for mRNA LNPs, we also refer the reader to 
[123]. Of note, the Dan Peer lab recently proposed a modular targeting platform for the 
selective delivery of (si)RNA LNPs to diverse leukocytes in vivo. Here, the conjugation of 
targeting antibodies was based on the incorporation of a lipoprotein inside the LNP system that 
non-covalently binds to the Fc domain of a selected targeting antibody [161, 162]. However, it 
should be noted that the incorporation of a targeting ligand adds an extra layer of complexity 
to the LNP system, involving additional synthetic steps, costs and regulatory hurdles [163]. 
Moreover, the targeting ability of such functionalized nanoparticles can be overruled by the 
deposition of endogenous proteins and the passive transport and clearance of nanoparticles 
[164]. Therefore, the potential clinical benefits of utilizing these targeting moieties for a specific 




Figure 5. Administration routes for mRNA vaccine delivery. Figure shows mRNA delivery 
options for both naked mRNA formats and nanoparticle-based strategies. 
4. The “self-adjuvant” effects of mRNA: The Good, the Bad, and the Ugly 
Contradictory results have been reported about the role of type I IFN responses on the 
immunogenicity of mRNA vaccines (see also section 2.3). A number of reports have revealed 
that the capacity of mRNA LNPs to evoke CTL responses strongly depended on the production 
of type I IFNs. Two papers showed that the i.v. administration of unmodified mRNA LNPs 
triggered a rapid and systemic induction of type I IFNs, which involved the selective targeting 
of DCs and macrophages and the activation of the TLR7 pathway [92, 136]. Experiments in 
mice with gene knockouts of the IFN-α receptor 1 (Ifnar1-/-) or TLR7 receptor (Tlr7-/-) 
demonstrated that the systemic type I IFN response evoked by mRNA LNPs was crucial to 
activate APCs and effector cells. Also, antitumor responses in a lung metastasis model were 
significantly impaired when tumor-bearing mice were immunized i.v. with mRNA LNPs while 
receiving i.p. injections with anti-IFNAR1 antibodies [92]. Comparative studies performed by 
our research group and others demonstrated that nucleoside-modified mRNA LNPs 
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outperformed unmodified mRNA LNPs in translation capacity, but failed to elicit successful 
CTL responses due to the drastically reduced production of type I IFNs [119, 157]. 
Where type I IFN is highly valuable to trigger an effective T cell response, other papers showed 
that an early type I IFN response inhibits the expression of antigen-encoding mRNA, which 
was rather detrimental for the mRNA vaccine’s outcome [165-167]. De Beuckelaer and 
colleagues demonstrated that the efficacy to evoke (CTL) antitumor immune responses in a 
B16 melanoma model of s.c. or i.d. administered DOTAP-DOPE mRNA LNPs, was strongly 
increased after type I IFN blockade [165]. For a self-amplifying mRNA LNP vaccine, Pepini et 
al. reported that the antigen expression was dramatically enhanced in the absence of IFN-α/β, 
which correlated with improved immunogenicity and IgG antibody responses [167]. 
Additionally, the robust and sustained antigen expression of nucleoside-modified mRNA was 
associated with more optimal antibody responses compared to unmodified mRNA [12, 13]. 
Clearly, this raises the fundamental question how to deal with the self-adjuvanticity of mRNA 
vaccines. In general, acute type I IFN responses mediate pleotropic and pro-inflammatory 
effects in both innate and adaptive immune cells [36, 168-171]. Indeed, type I IFN signalling 
induces DC maturation, improved antigen processing and presentation, and enhances DC 
migration to enriched T cell zones (e.g., via CCR7) [172-175]. Importantly, type I IFNs directly 
act as a signal 3 cytokine for T cell activation, promoting the clonal expansion, survival and 
effector differentiation of both CTLs and T helper cells [168, 172, 176]. In humoral immunity, 
type I IFNs promote the generation of long-lived antibody responses by the indirect 
enhancement of helper T cell responses and by direct immune-stimulatory effects on B cells 
[177, 178]. By regulating other pro-inflammatory cytokines, type I IFNs are also involved in the 
regulation of other immune cell types, such as Natural Killer (NK) cell responses [179].  
Lessons could potentially be learned from the detrimental role of type I IFNs during persistent 
viral infections. Here, it was found that chronic activation of the type I IFN pathway leads to the 
induction of regulatory DCs, the deletion of virus-specific B cells and strongly impaired T cells 
responses [180-182]. In an opinion article, De Beuckelaer et al. suggested that the type I IFN 
response by mRNA vaccines might have dual effects on naïve T cells, depending on the 
duration and relative timing between type I IFN signalling and T cell priming [169]. If type I IFNs 
are produced after recognition of MHC-presented antigens by T cells, they act as a strong 3rd 
signal cytokine to stimulate T cell activation and proliferation. By contrast, in case of a different 
timeframe, where the interaction between APCs and T cells is delayed or even absent, type I 
IFNs have completely opposite effects: rather than stimulating T cells, they activate an anti-
proliferative and pro-apoptotic programme [168]. This might explain why the early type I IFN 
response induced by an mRNA vaccine, might not only limit the mRNA-encoded antigen 
expression, but even exert deleterious effects on T cell responses [169]. 
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The involvement of type I IFNs in the regulation of immune tolerance, which can promote the 
development of autoreactive B cells and T cells, poses an even greater threat [183-185]. This 
can lead to severe autoimmune consequences, such as systemic lupus erythematosus and 
diabetes. As first clinical results with different mRNA vaccines have now been published, we 
learn more about their efficacy and potential side effects in humans, as summarized in Table 
1 and also reviewed in [38, 186]. Although the numbers of patients are still limited, Pardi et al. 
stated that some of the observed side effects of the clinically-tested mRNA vaccines might not 
be considered trivial, including the potential risks for autoimmune diseases [186]. In a phase 
I/IIa trial of a RNactive®-based vaccine for non-small cell lung carcinoma (NSCLC), common 
diagnostic indicators for autoimmunity were found to be elevated up to 20% of the patients 
after a RNactive® schedule of five intradermal injections (dose of 400-1600 µg) [187]. Another 
study testing the safety and immunogenicity of the RNactive® platform as prophylactic vaccine 
against rabies, elicited a moderate case of Bell’s palsy one week after a second i.m. 
administration of the highest dose of 640 µg (1/37 patients). This is a condition of temporary 
facial paralysis, which has been linked to autoimmunity [188]. 
How this complexity of type I IFN signalling on both efficacy and safety exactly relates to the 
design of an mRNA vaccine, requires further investigations. There is, however no doubt that 
distinct mRNA vaccines, varying in mRNA design, formulation and administration route, will 
exhibit differences in kinetics and cell-specificity for both mRNA expression and innate immune 
activation. Alterations in these mRNA vaccine parameters are therefore expected to impact on 
the role of type I IFN signalling on the mRNA vaccine’s outcome, thus deciding if it is good, 
bad, or ugly. Playing the devil’s advocate, it might also be possible that the induction of 
antibody responses versus CTL responses demands a shifted balance between the translation 
efficiency and type I IFN activity of mRNA vaccines, which might explain why unmodified 
mRNA vaccines were found to be more optimal to induce CTL responses, whereas superior 
antibody responses were detected for nucleoside-modified mRNA vaccines. Nevertheless, it 
can be expected that an mRNA vaccine that achieves high and sustained antigen availability, 
will benefit the magnitude and duration of both T cell and B cell responses [11, 189-191]. 
Excitingly, new imaging tools have been implemented in the evaluation of novel mRNA delivery 
systems, which allows visualization of mRNA pharmacology at the single cell and tissue level. 
This includes the generation of transgenic reporter mouse strains, such as the IFN-β reporter 
mice and Cre recombinase (mRNA) reporter mice, as well as the development of fluorescent 
imaging mRNA probes that allow to detect mRNA at high resolution [90, 158, 192-195]. To 
give an outstanding example, the Santangelo lab combined the delivery of fluorescently-
labelled mRNA with proximity-based assays [195]. As such, they were able to simultaneously 
detect cell-specific uptake, translation and in situ activation of the TLR7, RIG-I, MDA5 
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pathways upon the delivery of naked- or LNP formulated mRNA in the muscle of mice [194]. 
These different tools by which mRNA activities can be followed in real time, will be very helpful 
to identify differences between distinct mRNA vaccine platforms and to compare immunization 
routes. In combination with immunological read-outs and thorough safety assessments, this 
will support the development of more effective and safe mRNA vaccines. 
5. Beyond the type I IFN response 
Taking the dichotomous role of the anti-mRNA type I IFN response into account, we 
hypothesized that it could be of benefit to uncouple the translation and type I IFN activities of 
mRNA vaccines, and to replace the type I IFN response by another, more controllable immune 
activation. This strategy provides the freedom to optimize the mRNA construct to a high 
translation capacity, e.g., using nucleoside-modified mRNA, while chosing a “smarter” immune 
adjuvant: one that does not interfere with the mRNA translation process and that strongly 
contributes to effective but controllable immune responses. In a proof-of-concept study, we 
demonstrated that nucleoside-modified mRNA can be co-delivered with the clinically approved 
TLR agonist MPLA, achieving functional CTL responses like unmodified mRNA, but with 
strongly reduced type I IFN responses [157]. Additionally, we optimized a novel mRNA LNP 
platform which combines the in vivo delivery of nucleoside-modified mRNA and the Natural 
Killer T (NKT) cell ligand α-Galactosylceramide, named as mRNA Galsomes. By the dual 
“antigen” signalling to both conventional T cells and NKT cells, mRNA Galsomes were able to 
induce a relatively higher tumor influx of antigen-specific CTLs, NKT and NK cells, as well 
could reduce the tumor presence of immunosuppressive myeloid cells, compared to mice 
treated with type I IFN inducing LNPs formulated with unmodified mRNA [196].  
Besides this replacement of the type I IFN response by a more controllable immunostimulation, 
specific strategies are being developed within the framework of immunotherapy where 
avoiding the type I IFN response to ensure high protein expression, is beneficial. A first 
alternative to the de novo priming of adaptive immune cells, is to explore passive immunization 
approaches by using mRNA that directly encodes different antibody formats, including 
monoclonal antibodies, antibody fragments or bi-specific antibodies [197-200]. As the liver is 
the main target for many formulations after systemic delivery, this organ has been used as a 
biofactor for the production and secretion of mRNA-encoded proteins into the systemic. To 
give two examples, Thran et al. evaluated an LNP formulation of sequence-engineered mRNA 
coding for prophylactic or therapeutic antibodies. This could provide protection against rabies 
infection, botulinum intoxication, and tumors [201]. Stadler et al. designed mRNA constructs 
that encode bispecific antibodies directed against the T cell receptor associated molecule CD3 
and tumor antigens, referred to as RiboMABs [197]. This mRNA platform represented a valid 
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alternative to classic mRNA cancer vaccines, providing a strong infiltration of T cells able to 
eliminate tumors in mice. A second option, is to deliver mRNA encoding immunomodulatory 
molecules directly at the tumor site, such as cytokines and co-stimulatory molecules. Breckpot 
and colleagues demonstrated the reprogramming of DCs after the intratumoral administration 
of TriMix mRNA (i.e. CD40L, caTLR4 and CD70), or using mRNA encoding a fusokine 
consisting of IFN-β and the ectodomain of the TGF-β receptor II [84, 202]. In line with this, 
Moderna Therapeutics recently published on an anti-cancer immunotherapy, using direct 
intratumoral- and LNP-mediated delivery of a mixture of mRNA encoding IL-23, IL-36γ, and 
OX40(L) ligand [203]. By the localized expression of these immunomodulatory molecules, this 
strategy was able to break DC tolerance and to activate tumor-specific T cell responses. 
Furthermore, Van Hoecke et al. showed that established tumors could be turned into an in situ 
vaccine, mediated by electroporating tumors with mRNA that codes for the mixed lineage 
kinase domain-like (MLKL) protein [204]. Indeed, the expression of the MLKL provokes a type 
of immunogenic cell death, called necroptosis, which enables the release of tumor-specific 




Table 1: Clinical trials of mRNA vaccines with published (interim or complete) results  
 Clinical trial Antigen Administration Safety Efficacy 












200 µg (10x) 
Grade I/II: skin 
reactions 90%, pain 
49%, fatigue 37%, 
fever 12% 
-No evidence of clinical 
effectiveness 
Renal cell carcinoma 
[206, 207]  





300 µg (5-11x) 
Grade I/II: skin 
reactions, fever, 
headache 
- Induction of T cells 
- Long-term survival 








Melanoma [208]  






640 µg (12x) 
Grade I/II: skin 
reactions 50% grade II, 
and 40% grade I, 
fatigue 86%,pain 50%, 
headache 50%, fever 
40% 
- Induction of T cell 
response in subset of 
patients 
- reduced regulatory T cells 
- 1 CR of lung metastases 









Prostate cancer [209] 









- Grade I/II: erythema 
61%, injection site 
reaction 48%, fatigue 
18%, fever 16%, chills 
13% and influenza-like 
illness 11% 
- Grade III 11%; urinary 
retention, anemia, 
hematuria 
- T cell responses in 76% of 
evaluable patients 
- 1 patient with PSA 
response 
Non small cell lung 
carcinoma [187, 210] 
(46 patients, phase I/II) 
NCT00923312 
(26 patients, phase Ib 








1600 µg (5x) 
- Grade I/II: in most 
patients 
- Grade III 33%, mostly 
not drug-related 
- Serious AE 15%, but 
not considered drug-
related 
- Positive levels of 
diagnostic auto-
immune markers 20%  
- T cell responses in <30% 
of patients 
- Antigen-specific humoral 
responses: 47% 
-Increase in IgD+ CD38hi B 
cells, not related to antigen-
specific responses 
- No objective tumor 
responses 
Rabies [17] 







(needle syringe vs 
needle-free 
devices) 
80-640 µg (3x) 
- Injection site 
reactions (grade I/II) 
- Systemic adverse 
events, including grade 
III events  
- A case of transient, 
moderate Bell’s palsy 
- Protective antibody titers 
in 71% (i.d.) and 46% (i.m.) 
of vaccinated persons, after 
3 injections via needle-free 
device 
 












500 or 1000 µg 
(8x) 
No serious AEs  
(no further details) 
- Induction of T cells 
(against 60% of the 
predicted neo-epitopes) 




NCT, National Clinical Trial; AE, adverse events; CR, complete response; KLH, keyhole 
limpet hemocyanin, PSA, prostate specific antigen; HA(I), hemagglutinin (inhibition); MN, 
microneutralization. 
6. Combination of mRNA cancer vaccines with checkpoint therapies 
For mRNA therapeutics in oncology or for cancer vaccines in general, it might not be enough 
to activate effector immune responses against cancer. In addition, it is of crucial importance to 
keep a close eye on several immunosuppressive mechanisms that might hamper the evoked 
immunity. Upon the activation of T cells, the expression of checkpoint molecules forms a strong 
negative feedback loop to maintain T cell responses within a desired physiologic range. 
Overall, the immune system should rapidly act to discontinuities or potential danger, but at the 
same time an equilibrium should be established that maintains immune homeostasis [211-
213]. Several studies demonstrated that mRNA cancer vaccines upregulated the expression 
of the checkpoint molecules programmed death 1 (PD-1) on effector T cells, and its ligand 













7.2-29 µg  
(5-6x) 
No safety data 
reported  
- IFN-α and antigen-specific 
T cell responses 
 






Influenza [16, 18] 





25-400 µg (1-2x) 
Intradermal 
25-50 µg (1-2x) 
- Grade I/II: local and 
systemic 
- 3 reports (13%) of 
severe local AE after 
second dose in 100-µg 
group 
- High rates of solicited 
AEs associated with 
i.d. vaccination 
Immunogenicity after two 
i.m. injection of 100 µg 
mRNA dose: 
- HAI titers ≥ 40 in 100% of 
subjects (four times more 
than baseline). 
- MN ≥ 20 in 87%  
 Influenza [18] 





10, 25 and 50 µg 
(1-2x) 
 
- Grade I/II: local and 
systemic 
- Severe injection site 
pain after the second 
vaccination in 10% of 
participants in the 50-
µg dose group 
- HAI titers ≥ 40 after 2x 
mRNA doses of 10, 25 or 
50 µg in respectively 
36.0%, 96.3%, and 89.7% 
of participants 
- MN titers ≥ 20 (after 2x) in 
100% in the 10- and 25-µg 
groups and 96.6% 
in 50-µg group 
 
 














100-1200 µg (3x) 
31 grade I/II and 1 
grade III AE, mostly not 
considered as drug-
related 
-moderate HIV-specific T 





checkpoint pathway is mainly mediated by IFN-y, as well as can be induced by type I IFN 
responses [215-217]. 
As such, this sparks opportunity for combining mRNA vaccines with PD-1 checkpoint inhibitor 
treatments. Indeed, accumulating pre-clinical evidence shows that T cell responses and 
antitumor effects evoked by mRNA cancer therapeutics can strongly be strengthened by 
combining them with checkpoint inhibitors, such as anti-PD-1(L)-, and also anti-CTLA-4 
antibodies [135, 196, 214, 218, 219]. This also translates in the number of clinical trials (phase 
I/IIb) that are ongoing or recruiting patients to test the combination of mRNA vaccination with 
checkpoint inhibition for different cancer indications. In monotherapy, checkpoint inhibitors 
have resulted in impressive effects and durable responses in patients with highly refractory 
and late-stage cancers, such as metastatic melanoma and non-small cell lung cancer (NSCLC) 
[216]. However, only a subset of the patients benefits from these checkpoint therapies. 
Therefore, the establishment of effective combination therapies that could increase the 
response rate of checkpoint inhibitors is an area of intensive investigation [220, 221]. While 
(some) mRNA cancer vaccines have failed before to obtain objective clinical responses, the 
combination of these mRNA platforms with checkpoint inhibitors might represent a valuable 
approach (i) to ensure the longevity and continued effectiveness of the induced antitumor 
immunity and (ii) to contribute to a T cell inflamed tumor phenotype, rendering a larger group 
of patients responsive to checkpoint inhibition therapy.  
7. Conclusions and perspectives 
Starting from the earliest publications on the in vivo delivery of mRNA, this nucleic acid 
represents a versatile and promising platform for vaccination. In this review, we highlighted 
and explored the two key factors that can determine the mRNA vaccine’s chances of success.  
Firstly, it is essential to ensure adequate intracellular delivery of mRNA molecules, preferably 
by targeting APCs in vivo. Over the years, a fairly large knowledge gap about the in vivo 
behaviour of mRNA has been filled, both after the delivery of naked mRNA or when formulated 
in nanoparticles, and this for various immunization routes. Nowadays, there appears to be a 
trend towards the use of lipid-based nanoparticles for both localized and systemic delivery of 
mRNA. We discussed that the design of these LNPs asks for a multi-objective solving 
approach in which the overall mRNA transfection capacity will depend on trade-offs between 
different requirements to cross the extra- and intracellular barriers, while precautions are 
needed to prevent potential nanoparticle inherent (immune) toxicities. For clinical translation 
of these mRNA LNP systems, it will also be critical to meet pharmaceutical- and regulatory 
product requirements, going from scale-up manufacturing under GMP conditions, quality 
control of these products, stability testing, and good safety and efficacy assessments during 
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the pre-clinical stage in relevant animal models. Of note, the first approval by the FDA and 
EMA of an siRNA therapeutic (Onpattro™), utilizing an ionizable LNP technology for parental 
siRNA administration, may hopefully also serve as a seminal reference work for the future of 
mRNA vaccines.  
A second hard-to-find balance is the one between the mRNA-encoded antigen expression and 
adequate immunostimulation. Both parameters are of crucial importance to the vaccine 
outcome, but are inherently linked to the structural properties of the mRNA molecule itself. 
More specifically, although the mRNA-induced type I IFN response might add to the 
immunogenicity of the mRNA vaccine, it also interferes with the mRNA-encoded antigen 
expression and possibly even lead to deleterious immune effects. Fundamental research 
should further focus on how to control the type I IFN activity of mRNA vaccines, which might 
vary depending on the mRNA formulation, administration route, the individual patient and the 
intended therapeutic application. As such, mRNA approaches which do not necessarily rely on 
the self-adjuvant effect of mRNA are one the rise, such as the replacement of type I IFN 
responses by more controllable adjuvant systems, or using mRNA for passive immunization 
approaches. The question whether these novel strategies might offer benefits over the 
“conventional” mRNA vaccines is a topic worthy of further exploration.  
These are exciting times with different biotech companies bringing mRNA therapeutics towards 
clinical translation. In the near future, mRNA cancer vaccines targeting mutation-derived 
epitopes (neoantigens) might become an attractive alternative to other clinically-advanced 
cancer vaccines, such as those composed with synthetic (long) peptides and immune 
adjuvants [222-224]. Here, it can be expected that the future clinical trials testing the 
combination of (personalized) mRNA cancer vaccines with checkpoint inhibition will have a 
better chance for success, however, the safety and optimization of such combination therapies 
will be another topic of investigation. For prophylactic mRNA vaccines against infectious 
diseases, (pre-)clinical studies (in non-human primates) show accumulating evidence that 
mRNA vaccination is feasible, generally well-tolerated, and potentially beneficial over other 
traditional vaccine approaches. However, it is still waiting for a more extended clinical 
experience on how patients respond to mRNA vaccines, including more comparative research 
to select for the best suited mRNA platform and administration route, as well as to show clear 
therapeutic benefits over other vaccine strategies. Together, it is but a matter of time before 
we will be able to determine which of these mRNA vaccine candidates/strategies enable 
effective but safe immune responses in humans, hopefully leading to a new generation of 
vaccines.  
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